BC
CPRX

Bridgefront Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Bridgefront Capital’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$555K Buy
+22,398
New +$534K 0.14% 250
2023
Q2 		– Sell
-10,340
Closed -$171K – 492
2023
Q1 		$171K Sell
10,340
-6,931
-40% -$114K 0.1% 362
2022
Q4 		$321K Buy
+17,271
New +$266K 0.22% 192
2021
Q3 		– Sell
-27,460
Closed -$158K – 401
2021
Q2 		$158K Buy
27,460
+6,834
+33% +$35.3K 0.06% 527
2021
Q1 		$95K Buy
+20,626
New +$81.9K 0.03% 625

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bridgefront Capital's CPRX Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 22,398 shares worth $555K. The stake represents 0.14% of the portfolio and ranks #250 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in CPRX as recently as Q1 2023.

Bridgefront Capital first reported a position in CPRX in Q1 2021 and has held it in 5 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Bridgefront Capital held 22,398 shares of Catalyst Pharmaceutical worth $555K as of Q1 2026.
  • Catalyst Pharmaceutical was a new Bridgefront Capital position in Q1 2026.
  • Catalyst Pharmaceutical made up 0.14% of Bridgefront Capital's portfolio in Q1 2026, its #250 holding.
  • Bridgefront Capital first reported a position in Catalyst Pharmaceutical in Q1 2021 and has held it in 5 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.